ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1617

New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network

Julia Harris1, Esi Morgan2, Sheetal Vora3, Mileka Gilbert4, Cagri Yildirim-Toruner5, Nancy Griffin6, Kerry Ferraro7, Stephanie Loos6, Tingting Qiu8, Anne Paul9, Jon Burnham10, Michelle Batthish11, Beth Gottlieb12, Danielle Bullock13, Melissa Hazen14, Ronald Laxer15, Tzielan Lee16, Melissa Mannion17, Judyann Olson18, Nancy Pan19, Michael Shishov20, Charles Spencer21, Jennifer E Weiss22 and C. April Bingham23, 1Children's Mercy Kansas City, Overland Park, KS, 2Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Atrium Health Levine Children's Hospital, Charlotte, NC, 4Medical University of South Carolina, Charleston, SC, 5Nationwide Children's Hospital, Houston, TX, 6Cincinnati Children's Hospital Medical Center, Cincinnati, 7Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, 8Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, 10Children's Hospital of Philadelphia, Philadelphia, PA, 11McMaster Children's Hospital, Hamilton, ON, Canada, 12Cohen Children's Medical Center, Lake Success, NY, 13University of Minnesota, Minneapolis, MN, 14Boston Children's Hospital, Boston, MA, 15The Hospital for Sick Children, Toronto, ON, Canada, 16Stanford University School of Medicine, Palo Alto, CA, 17University of Alabama at Birmingham, Birmingham, AL, 18Medical College of Wisconsin, Milwaukee, WI, 19Hospital for Special Surgery, New York, NY, 20Phoenix Children's Hospital, Phoenix, AZ, 21University of Mississippi, Jackson, MS, 22PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 23Penn State Children's Hospital, Allentown, PA

Meeting: ACR Convergence 2020

Keywords: Juvenile idiopathic arthritis, Outcome measures, Pediatric rheumatology, quality of care

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Measures & Measurement of Healthcare Quality Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning network to support pediatric rheumatology centers in improving care delivery and patient outcomes. This growing network, now 21 centers, was established in 2011 and has tracked outcome and process measures over time. PR-COIN recently modified its quality measure (QM) set that coincided with a registry migration of 5,905 patients to a new platform to support optimal data reporting. This report highlights the network’s new QMs and provides some performance on these measures from a large JIA cohort enrolled in the network registry.  

Methods: The network’s initial process measures were based on a published set of QMs for JIA that was developed utilizing an evidence-based approach and consensus methodology. Outcome measures were created using published, validated JIA outcome assessments. Taking into consideration 3 main measure attributes – clinical health importance, scientific validity, and feasibility – in addition to new best practices, PR-COIN modified the QM set in 2019 with parent input and developed operational definitions. QMs were tested using patient data for validation. Network teams enter and/or auto-upload patient data into the PR-COIN registry to populate the measures, and statistical process control charts are utilized to display monthly performance.

Results: PR-COIN’s QM set consists of 20 measures, including 16 clinical and 4 data quality measures (Table 1). Outcome measures for disease control include evaluation of the clinical Juvenile Arthritis Disease Activity Score (cJADAS10), clinically inactive disease, the active joint count, and the time to inactive disease. Patient-reported outcomes are comprised of optimal physical function, low or no pain, low patient global assessment of overall well-being, and low pain interference. Treat to Target interventions, including setting a treatment target and use of clinical decision support, will be tracked as process measures in addition to the use of self-management support and appropriate medication safety monitoring. A new balancing measure regarding infection-related hospitalizations rounds out the QM set. Figure 1 is an example run chart of a disease control outcome measure – mean disease activity score by cJADAS10 (scale 0-30) of all JIA patients – demonstrating the aggregate performance of 8 PR-COIN sites. This cumulative measure has been stable at 2.5 over the last 5 months. Figure 2 is an example run chart using collaborative data of a patient-reported quality of life outcome measure, the mean patient global assessment of well-being (scale 0-10). This score has been around 1.26 for the last several months.

Conclusion: PR-COIN has enhanced its comprehensive and varied QM set for the care of patients with JIA. Having clinically important measures that are tested for feasibility on a large cohort of patients with JIA can maximize quality improvement efforts to optimize care delivery.

Table 1. PR-COIN Quality Measures for Juvenile Idiopathic Arthritis.

Figure 1. Mean disease activity score by cJADAS10 of JIA patients in PR-COIN.

Figure 2. Mean patient global assessment of well-being score for JIA patients in PR-COIN.


Disclosure: J. Harris, None; E. Morgan, None; S. Vora, None; M. Gilbert, None; C. Yildirim-Toruner, None; N. Griffin, None; K. Ferraro, None; S. Loos, None; T. Qiu, None; A. Paul, None; J. Burnham, None; M. Batthish, Abbvie, 2; B. Gottlieb, None; D. Bullock, None; M. Hazen, None; R. Laxer, Eli Lilly Canada, 1, Novartis, 1, Sanofi, 1; T. Lee, None; M. Mannion, None; J. Olson, Abbvie, 1, BMS, 1; N. Pan, None; M. Shishov, None; C. Spencer, None; J. Weiss, None; C. Bingham, None.

To cite this abstract in AMA style:

Harris J, Morgan E, Vora S, Gilbert M, Yildirim-Toruner C, Griffin N, Ferraro K, Loos S, Qiu T, Paul A, Burnham J, Batthish M, Gottlieb B, Bullock D, Hazen M, Laxer R, Lee T, Mannion M, Olson J, Pan N, Shishov M, Spencer C, Weiss J, Bingham C. New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/new-juvenile-idiopathic-arthritis-quality-measure-set-for-the-pediatric-rheumatology-care-and-outcomes-improvement-network-2/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-juvenile-idiopathic-arthritis-quality-measure-set-for-the-pediatric-rheumatology-care-and-outcomes-improvement-network-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology